Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

Sage Therapeutics, Inc. - Special Call Transcript

Dec 05, 2019 / 01:30PM GMT
Release Date Price: €56.5 (-58.15%)
Operator

Good morning. Welcome to Sage Therapeutics' conference call to discuss results from the Phase III MOUNTAIN Study. (Operator Instructions)

This call is being webcast live on the Investors & Media section of Sage's website at sagerx.com. This call is the property of Sage Therapeutics, and recording, reproduction or transmission of this call without the express written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.

I would now like to introduce Matthew Calistri, Investor Relations at Sage.

Matthew Calistri
Sage Therapeutics, Inc. - VP of IR

Hello, and thank you for joining Sage Therapeutics' conference call to discuss top line results of our pivotal Phase III MOUNTAIN Study of SAGE-217 in major depressive disorder. Before we begin, I encourage everyone to go to the Investors & Media section of our website at sagerx.com, where you can find the press release related to today's call as well as the slides that contain additional details.

I would like to point out that we will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot